<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1995, the Japan <z:mp ids='MP_0002055'>Diabetes</z:mp> Society (JDS) appointed the Committee for the Classification and Diagnosis of <z:hpo ids='HP_0000819'>Diabetes Mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The Committee presented a final report in May 1999 in Japanese </plain></SENT>
<SENT sid="2" pm="."><plain>This is the English version with minor modifications for readers outside Japan </plain></SENT>
<SENT sid="3" pm="."><plain>CONCEPT OF <z:e sem="disease" ids="C0011849" disease_type="Disease or Syndrome" abbrv="dm">DIABETES MELLITUS</z:e>: <z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo> represents a group of diseases of <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> etiology, characterized by <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and other <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp>, which are due to deficiency of insulin effect </plain></SENT>
<SENT sid="4" pm="."><plain>After a long duration of metabolic derangement, specific complications of <z:mp ids='MP_0002055'>diabetes</z:mp> (<z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>) may occur </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002634'>Arteriosclerosis</z:hpo> is also accelerated </plain></SENT>
<SENT sid="6" pm="."><plain>Depending on the severity of the metabolic abnormality, <z:mp ids='MP_0002055'>diabetes</z:mp> may be asymptomatic, or may be associated with symptoms (thirst, <z:hpo ids='HP_0000103'>polyuria</z:hpo>, and <z:hpo ids='HP_0001824'>weight loss</z:hpo>), or may progress to <z:hpo ids='HP_0001993'>ketoacidosis</z:hpo> and <z:hpo ids='HP_0001259'>coma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CLASSIFICATION: Both etiological classification and staging of pathophysiology by the degree of deficiency of insulin effect need to be considered </plain></SENT>
<SENT sid="8" pm="."><plain>The etiological classification of <z:mp ids='MP_0002055'>diabetes</z:mp> and related disorders of glycemia includes, (1) type 1; (2) type 2; (3) those due to specific mechanisms and diseases; and (4) <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> mellitus </plain></SENT>
<SENT sid="9" pm="."><plain>Type 1 is characterized by destructive lesions of pancreatic beta cells either by an autoimmune mechanism or of unknown cause </plain></SENT>
<SENT sid="10" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterized by combinations of <z:mp ids='MP_0003059'>decreased insulin secretion</z:mp> and decreased insulin sensitivity (<z:hpo ids='HP_0000855'>insulin resistance</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain>Category (3) includes two subgroups; subgroup A is <z:mp ids='MP_0002055'>diabetes</z:mp> in which specific mutations have been identified as a cause of genetic susceptibility, while subgroup B is <z:mp ids='MP_0002055'>diabetes</z:mp> associated with other pathologic conditions or diseases </plain></SENT>
<SENT sid="12" pm="."><plain>The staging of <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism includes <z:mpath ids='MPATH_458'>normal</z:mpath>, borderline and diabetic stages </plain></SENT>
<SENT sid="13" pm="."><plain>The diabetic stage is further classified into three substages; non-insulin requiring, insulin-requiring for glycemic control, and insulin-dependent (ID) for survival </plain></SENT>
<SENT sid="14" pm="."><plain>In each individual, these stages may vary according to the deterioration or the improvement of the metabolic state, either spontaneously or by treatment </plain></SENT>
<SENT sid="15" pm="."><plain>DIAGNOSIS: The confirmation of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> is a prerequisite for the diagnosis of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>The state of glycemia may be classified within three categories, diabetic type; borderline type; and <z:mpath ids='MPATH_458'>normal</z:mpath> type </plain></SENT>
<SENT sid="17" pm="."><plain>Diabetic type is defined when fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) is 7.0 mmol/l (126 mg/dl) or higher, and/or plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> 2 h after 75 g <z:chebi fb="105" ids="17234">glucose</z:chebi> load (2hPG) is 11.1 mmol/l (200 mg/dl) or higher </plain></SENT>
<SENT sid="18" pm="."><plain>A casual plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (PG) &gt; or =11.1 mmol/l (200 mg/dl) also indicates diabetic type </plain></SENT>
<SENT sid="19" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> type is defined when FPG is below 6.1 mmol/l (110 mg/dl) and 2hPG below 7.8 mmol/l (140 mg/dl) </plain></SENT>
<SENT sid="20" pm="."><plain>Borderline type includes those who are neither diabetic nor <z:mpath ids='MPATH_458'>normal</z:mpath> types </plain></SENT>
<SENT sid="21" pm="."><plain>These cutoff values are for venous PG measurements </plain></SENT>
<SENT sid="22" pm="."><plain>The persistence of 'diabetic type' in a subject indicates that he or she has <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="23" pm="."><plain>For children, a dose of 1.75 g/kg (maximum, 75 g) is used for oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT) </plain></SENT>
<SENT sid="24" pm="."><plain>The procedure for clinical diagnosis is as follows </plain></SENT>
<SENT sid="25" pm="."><plain><z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo> is diagnosed when <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> meeting the criteria for 'diabetic type' is shown on two or more occasions examined on separate days </plain></SENT>
<SENT sid="26" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> can be diagnosed by a single PG test of 'diabetic type' if one of the following three conditions co-exists, (1) typical symptoms of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>; (2) HbA1c &gt; or =6.5% by a standardized method; or (3) unequivocal diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="27" pm="."><plain>If the above conditions ((1) or (2)) have been present in the past and well documented, the subject is diagnosed either to have <z:mp ids='MP_0002055'>diabetes</z:mp> or to be suspected of <z:mp ids='MP_0002055'>diabetes</z:mp>, even if the present level of glycemia does not reach that of 'diabetic type' </plain></SENT>
<SENT sid="28" pm="."><plain>If the diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> cannot be established by these procedures, re-testing of PG is recommended after an appropriate interval </plain></SENT>
<SENT sid="29" pm="."><plain>The physician should assess not only the presence or absence of <z:mp ids='MP_0002055'>diabetes</z:mp>, but also its etiology and glycemic stage, and the presence and absence of <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> or associated conditions </plain></SENT>
<SENT sid="30" pm="."><plain>EPIDEMIOLOGICAL ASPECTS AND SCREENING: In order to determine the prevalence of <z:mp ids='MP_0002055'>diabetes</z:mp> in a population, 'diabetic type' may be regarded as '<z:mp ids='MP_0002055'>diabetes</z:mp>' </plain></SENT>
<SENT sid="31" pm="."><plain>The use of 2hPG cutoff level of &gt; or =11.1 mmol/l (200 mg/dl) is recommended </plain></SENT>
<SENT sid="32" pm="."><plain>If this is difficult, the FPG cutoff level of &gt; or =7.0 mmol/l (126 mg/dl) can be used, but is likely to lead to under-ascertainment </plain></SENT>
<SENT sid="33" pm="."><plain>For screening, the most important point is not to overlook '<z:mp ids='MP_0002055'>diabetes</z:mp>' </plain></SENT>
<SENT sid="34" pm="."><plain>In addition to parameters of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, clinical information such as family history, <z:hpo ids='HP_0001513'>obesity</z:hpo> etc., should be regarded as indications for further testing </plain></SENT>
<SENT sid="35" pm="."><plain>NORMAL TYPE AND BORDERLINE: Only FPG and 2hPG are adopted as cutoff values, but in clinical situations, it is recommended to measure PG also at 30 and 60 min during 75 g OGTT </plain></SENT>
<SENT sid="36" pm="."><plain>Among people with <z:mpath ids='MPATH_458'>normal</z:mpath> type, those with 1hPG higher than 10.0 mmol/l (180 mg/dl) are at higher risk to develop <z:mp ids='MP_0002055'>diabetes</z:mp> than those with lower 1hPG </plain></SENT>
<SENT sid="37" pm="."><plain>When OGTT is performed, the borderline type corresponds to the sum of impaired fasting glycemia (IFG) plus <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) according to the new WHO report </plain></SENT>
<SENT sid="38" pm="."><plain>Subjects in this category are at higher risk of developing <z:mp ids='MP_0002055'>diabetes</z:mp> than those with '<z:mpath ids='MPATH_458'>normal</z:mpath> type' </plain></SENT>
<SENT sid="39" pm="."><plain>Those with low insulinogenic index (the ratio of increment of plasma insulin to that of PG at 30 min during OGTT) are at particularly high risk to develop <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="40" pm="."><plain>Microvascular complications are rare but arteriosclerotic complications are fairly frequent in this category </plain></SENT>
<SENT sid="41" pm="."><plain>GESTATIONAL <z:e sem="disease" ids="C0011849" disease_type="Disease or Syndrome" abbrv="dm">DIABETES MELLITUS</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e>): The current definition of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> is ' any <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> developed or detected during pregnancy' </plain></SENT>
<SENT sid="42" pm="."><plain>We adopt the proposal of the Japan Society of Gynecology and Obstetrics for the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> (1984) </plain></SENT>
<SENT sid="43" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> is defined when two or more values during a 75 g OGTT are higher than the following cutoff levels; FPG &gt; or =5.5 mmol/l (100 mg/dl), 1hPG &gt; or =10.0 mmol/l (180 mg/dl) and 2hPG &gt; or =8.3 mmol/l (150 mg/dl) </plain></SENT>
<SENT sid="44" pm="."><plain>As a screening test, subjects with casual PG &gt; or =5.5 mmol/l (100 mg/dl) are recommended for further testing </plain></SENT>
<SENT sid="45" pm="."><plain>Patients who have had documented <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> before pregnancy, and who present as 'diabetic type' should be under closer supervision than those who develop <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> during pregnancy for the first time </plain></SENT>
<SENT sid="46" pm="."><plain>HbA1c: There is a large overlap in the distribution of HbA1c between groups with '<z:mpath ids='MPATH_458'>normal</z:mpath> type' and 'borderline type' and mild 'diabetic type' </plain></SENT>
<SENT sid="47" pm="."><plain>Therefore, HbA1c is not a suitable parameter to detect mild <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> </plain></SENT>
<SENT sid="48" pm="."><plain>HbA1c higher than 6.5% suggests <z:mp ids='MP_0002055'>diabetes</z:mp>, but HbA1c below 6.5% alone should not be taken as evidence against the diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="49" pm="."><plain>COMPARISON WITH REPORTS OF AMERICAN DIABETES ASSOCIATION (<z:chebi fb="36" ids="39048">ADA</z:chebi>) IN 1997 AND WHO IN 1999: The present report is unique in the following points when compared with those of the <z:chebi fb="36" ids="39048">ADA</z:chebi> '<z:mp ids='MP_0002055'>Diabetes</z:mp> Care 20 (1997) 1183' and WHO 'Report of a WHO Consultation (1999)' </plain></SENT>
<SENT sid="50" pm="."><plain>(1) <z:mp ids='MP_0002055'>Diabetes</z:mp> due to specific mechanisms and diseases is divided into two subgroups; <z:mp ids='MP_0002055'>diabetes</z:mp> in which genetic susceptibility is clarified at the DNA level and <z:mp ids='MP_0002055'>diabetes</z:mp> associated with other diseases or conditions </plain></SENT>
<SENT sid="51" pm="."><plain>(2) Cutoff PG levels are the same as those of <z:chebi fb="36" ids="39048">ADA</z:chebi> and WHO, but a term 'type' is added to each glycemic category, because a single coding of 'diabetic type' <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> does not define <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="52" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> is diagnosed when 'diabetic type' <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> is shown on two or more occasions </plain></SENT>
<SENT sid="53" pm="."><plain>(3) A single 'diabetic type' <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> is considered sufficient for the diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp>, if the patient has typical symptoms, HbA1c &gt; or =6.5%, or diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="54" pm="."><plain>(4) OGTT is recommended for those with mild <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, because FPG criteria alone would overlook many subjects with 'diabetic type' in Japan </plain></SENT>
<SENT sid="55" pm="."><plain>High 1hPG without elevation of FPG and 2hPG is also considered to be a risk factor for future <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="56" pm="."><plain>(5) Borderline type in the present report corresponds to the sum of IFG and IGT by WHO when OGTT is performed </plain></SENT>
<SENT sid="57" pm="."><plain>(6) New criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> by OGTT are proposed </plain></SENT>
</text></document>